Ignite Creation Date:
2025-12-24 @ 4:39 PM
Ignite Modification Date:
2025-12-29 @ 11:01 AM
Study NCT ID:
NCT05108766
Status:
COMPLETED
Last Update Posted:
2023-04-12
First Post:
2021-10-27
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase Ⅲ Study to Evaluate Tildrakizumab in the Treatment of Chinese Subjects With Moderate to Severe Plaquetype Psoriasis
Sponsor:
Shenzhen Kangzhe Pharmaceutical Co., Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-12-17
Start Date Type:
ACTUAL
Primary Completion Date:
2021-06-07
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-07-08
Completion Date Type:
ACTUAL
First Submit Date:
2021-10-27
First Submit QC Date:
None
Study First Post Date:
2021-11-05
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-04-10
Last Update Post Date:
2023-04-12
Last Update Post Date Type:
ACTUAL